{
     "PMID": "9489732",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "19980312",
     "LR": "20171116",
     "IS": "0022-3042 (Print) 0022-3042 (Linking)",
     "VI": "70",
     "IP": "3",
     "DP": "1998 Mar",
     "TI": "Selective increase of alpha2A-adrenoceptor agonist binding sites in brains of depressed suicide victims.",
     "PG": "1114-23",
     "AB": "The alpha2A- and alpha2C-adrenoceptor subtypes were evaluated in postmortem brains from suicides with depression (n = 22), suicides with other diagnoses (n = 12), and controls (n = 26). Membrane assays with the antagonist [3H]RX821002 (2-[3H]methoxyidazoxan) suggested the presence of alpha2A-adrenoceptors in the frontal cortex and both alpha2C-adrenoceptors and alpha2A-adrenoceptors in the caudate. The proportions in caudate were similar in controls (alpha2A, 86%; alpha2C, 14%), depressed suicides (alpha2A, 91%; alpha2C, 9%), and suicides with other diagnoses (alpha2A, 88%; alpha2C, 12%). Autoradiography of [3H]RX821002 binding under alpha(2B/C)-adrenoceptor-masking conditions confirmed the similar densities of alpha2A-adrenoceptors in the cortex, hippocampus, and striatum from controls and suicides. In the frontal cortex of depressed suicides, competition of [3H]RX821002 binding by (-)-adrenaline revealed a greater proportion (61 +/- 9%) of alpha2A-adrenoceptors in the high-affinity conformation for agonists than in controls (39 +/- 5%). Simultaneous analysis with the agonists [3H]clonidine and [3H]UK14304 and the antagonist [3H]RX821002 in the same depressed suicides confirmed the enhanced alpha2A-adrenoceptor density when evaluated by agonist, but not by antagonist, radioligands. The results indicate that depression is associated with a selective increase in the high-affinity conformation of the brain alpha2A-adrenoceptors.",
     "FAU": [
          "Callado, L F",
          "Meana, J J",
          "Grijalba, B",
          "Pazos, A",
          "Sastre, M",
          "Garcia-Sevilla, J A"
     ],
     "AU": [
          "Callado LF",
          "Meana JJ",
          "Grijalba B",
          "Pazos A",
          "Sastre M",
          "Garcia-Sevilla JA"
     ],
     "AD": "Department of Pharmacology, University of the Basque Country, Leioa, Bizkaia, Spain.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "PL": "England",
     "TA": "J Neurochem",
     "JT": "Journal of neurochemistry",
     "JID": "2985190R",
     "RN": [
          "0 (Adrenergic alpha-Agonists)",
          "0 (Adrenergic alpha-Antagonists)",
          "0 (Quinoxalines)",
          "0 (Receptors, Adrenergic, alpha-2)",
          "10028-17-8 (Tritium)",
          "4S9CL2DY2H (Brimonidine Tartrate)",
          "E27LB7P0ET (2-methoxyidazoxan)",
          "MN3L5RMN02 (Clonidine)",
          "Y310PA316B (Idazoxan)"
     ],
     "SB": "IM",
     "MH": [
          "Adrenergic alpha-Agonists/pharmacology",
          "Adrenergic alpha-Antagonists/pharmacology",
          "Adult",
          "Autoradiography",
          "Binding, Competitive",
          "Brain Chemistry/*physiology",
          "Brimonidine Tartrate",
          "Cell Membrane/chemistry",
          "Clonidine/pharmacology",
          "Depression/*metabolism",
          "Female",
          "Frontal Lobe/chemistry/metabolism",
          "Humans",
          "Idazoxan/analogs & derivatives/pharmacology",
          "Male",
          "Middle Aged",
          "Quinoxalines/pharmacology",
          "Receptors, Adrenergic, alpha-2/*metabolism",
          "*Suicide",
          "Tritium"
     ],
     "EDAT": "1998/03/07 00:00",
     "MHDA": "1998/03/07 00:01",
     "CRDT": [
          "1998/03/07 00:00"
     ],
     "PHST": [
          "1998/03/07 00:00 [pubmed]",
          "1998/03/07 00:01 [medline]",
          "1998/03/07 00:00 [entrez]"
     ],
     "PST": "ppublish",
     "SO": "J Neurochem. 1998 Mar;70(3):1114-23.",
     "term": "hippocampus"
}